Related Experiment Video

Updated: Jun 16, 2026

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Indomethacin-5-fluorouracil-methyl ester dry emulsion: a potential oral delivery system for 5-fluorouracil

Jing Wang1, Yanchen Hu, Ling Li

  • 1School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning Province, PR China. Wang-jing6312@163.com

Drug Development and Industrial Pharmacy
|February 9, 2010
PubMed
Abstract

Insights

A novel Indomethacin-5-fluorouracil-methyl ester (IFM) dry emulsion was developed to improve oral cancer therapy. This formulation aims to reduce indomethacin

Area of Science:

  • Pharmaceutical Sciences
  • Drug Delivery Systems
  • Cancer Therapy

Background:

  • Indomethacin (IDM) and 5-fluorouracil (5FU) combination therapy shows promise for cancer treatment.
  • Challenges include IDM's gastrointestinal side effects and 5FU's poor oral absorption.

Purpose of the Study:

  • To develop an Indomethacin-5-fluorouracil-methyl ester (IFM) dry emulsion for enhanced oral delivery.
  • To mitigate IDM's GI toxicity and improve 5FU's oral bioavailability.

Main Methods:

  • Synthesis and characterization of IFM, including physicochemical properties.
  • Preparation of IFM dry emulsion using gum acacia and sodium carboxymethyl cellulose.
  • Evaluation of IFM dry emulsion via reconstitution and in situ intestinal perfusion.

Main Results:

  • Successful synthesis and characterization of IFM confirmed its formation.
  • IFM dry emulsion showed good reconstitution properties with a mean particle size of 2.416 microm.
  • In situ perfusion studies indicated passive diffusion of IFM, with absorption rate constants suggesting potential for oral delivery.

Conclusions:

  • The developed IFM dry emulsion shows potential as an oral delivery system for 5FU.
  • This formulation may offer a strategy to improve cancer therapy by combining IDM and 5FU effectively.

Related Concept Videos

Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
Oral Drug Delivery Systems: Introduction01:23

Oral Drug Delivery Systems: Introduction

Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...